Zhou et al. BMC Cancer 2010, 10:653 http://www.biomedcentral.com/1471-2407/10/653 28. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005, 116(3):340-350. 29. Tang P, Wang J, Bourne P: Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum Pathol 2008, 39(4):506-513. 30. Tang P, Skinner KA, Hicks DG: Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol 2009, 18(3):125-132. 31. Francis GD, Jones MA, Beadle GF, Stein SR: Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol 2009, 18(2):88-95. 32. Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B: Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 2009, 54(2):248-253. 33. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD, DeWitty RL, Frederick WA: Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg 2008, 247(3):463-469. 34. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, et al: Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007, 16(3):439-443. 35. [http://www.swebcg.se/index.asp?P=NatRikt]. 36. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res 2009, 7(1-2):4-13. 37. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil- Bertram S, Traut A, Bois AD: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009. 38. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW: The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009. 39. Thike AA, Iqbal J, Cheok PY, Chong AP, Tse GM, Tan B, Tan P, Wong NS, Tan PH: Triple Negative Breast Cancer: Outcome Correlation With Immunohistochemical Detection of Basal Markers. Am J Surg Pathol . 40. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA et al: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15(7):2302-2310. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/10/653/prepub doi:10.1186/1471-2407-10-653 Cite this article as: Zhou et al.: Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer 2010 10:653. Page 8 of 8 Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit